What the physicians should know about mast cells, dendritic cells, urticaria, and omalizumab duringCOVID-19 or asymptomatic infections due toSARS-CoV-2?

Imagem de Miniatura
Arquivos
art_CRIADO_What_the_physicians_should_know_about_mast_cells_2020.PDF (6.74 MB)
Citações na Scopus
23
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY
Autores
CRIADO, Roberta Fachini Jardim
Citação
DERMATOLOGIC THERAPY, v.33, n.6, article ID e14068, 9p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Coronavirus disease (COVID-19) pandemic presents several dermatological manifestations described in the present indexed literature, with around 700 cases reported until May 2020, some described as urticaria or urticarial rashes. Urticaria is constituted by evanescent erythematous-edematous lesions (wheals and flare), which does not persist in the same site for more than 24 to 48 hours and appears in other topographic localization, resolving without residual hyper pigmentation. During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, some cytokines are synthesized, including Interferon (IFN) type I, TNF-alpha, and chemokines which may induce mast cells (MCs) and basophils degranulation by mechanisms similar to the autoinflammatory monogenic or polygenic diseases. In this article, we discuss the spectrum of the urticaria and urticarial-like lesions in the COVID-19's era, besides other aspects related to innate and adaptative immune response to viral infections, interactions between dermal dendritic cells and MCs, and degranulation of MCs by different stimuli. Plasmacytoid dendritic cells share, in allergic patients, expression of the high-affinity IgE receptors on cell membranes and demonstrated a low pattern of type I IFN secretion in viral infections. We discuss the previous descriptions of the effects of omalizumab, a monoclonal antibody directed to IgE and high-affinity IgE receptors, to improve the IFN responses and enhance their antiviral effects.
Palavras-chave
COVID-19, dendritic cells, innate immunity, mast cells, SARS-CoV-2, urticaria
URI
https://observatorio.fm.usp.br/handle/OPI/39159
Referências
  1. Aghdam MK, 2020, INFECT DIS-NOR, V52, P427, DOI 10.1080/23744235.2020.1747634
  2. Atta AM, 2010, INT ARCH ALLERGY IMM, V152, P401, DOI 10.1159/000288293
  3. Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705
  4. Buttignol M, 2017, RESP RES, V18, DOI 10.1186/s12931-017-0630-x
  5. Cardet JC, 2019, J ALLERGY CLIN IMMUN, V143, P923, DOI 10.1016/j.jaci.2019.01.016
  6. Charles N, 2010, NAT MED, V16, P701, DOI 10.1038/nm.2159
  7. Chen Y, 2020, J MED VIROL, V92, P418, DOI 10.1002/jmv.25681
  8. Cheng YD, 2019, J INFECT PUBLIC HEAL, V12, P878, DOI 10.1016/j.jiph.2019.05.017
  9. Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462
  10. Crowl JT, 2017, ANNU REV IMMUNOL, V35, P313, DOI 10.1146/annurev-immunol-051116-052331
  11. Dema B, 2014, J EXP MED, V211, P2159, DOI 10.1084/jem.20140066
  12. Dema B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090424
  13. Dong X, 2020, ALLERGY, V75, P1699, DOI 10.1111/all.14289
  14. Dudeck A, 2019, J ALLERGY CLIN IMMUN, V144, pS4, DOI 10.1016/j.jaci.2018.10.054
  15. Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023
  16. Esquivel A, 2017, AM J RESP CRIT CARE, V196, P985, DOI 10.1164/rccm.201701-0120OC
  17. Ferro F, 2020, CLIN EXP RHEUMATOL, V38, P175
  18. Fukuda M, 2013, J INNATE IMMUN, V5, P163, DOI 10.1159/000343895
  19. Gill MA, 2018, J ALLERGY CLIN IMMUN, V141, P1735, DOI 10.1016/j.jaci.2017.07.035
  20. Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194
  21. Graham AC, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00238
  22. Hamming I, 2004, J PATHOL, V203, P631, DOI 10.1002/path.1570
  23. Hasni S, 2019, ARTHRITIS RHEUMATOL, V71, P1135, DOI 10.1002/art.40828
  24. Henault J, 2016, NAT IMMUNOL, V17, P196, DOI 10.1038/ni.3326
  25. Igawa S, 2017, TRANSL RES, V184, P68, DOI 10.1016/j.trsl.2017.03.003
  26. Jegalian AG, 2009, ADV ANAT PATHOL, V16, P392, DOI 10.1097/PAP.0b013e3181bb6bc2
  27. Kantor DB, 2016, J ALLERGY CLIN IMMUN, V138, P1467, DOI 10.1016/j.jaci.2016.04.044
  28. King CA, 2000, J VIROL, V74, P7146, DOI 10.1128/JVI.74.15.7146-7150.2000
  29. Kritas SK, 2020, J BIOL REG HOMEOS AG, V34, P9, DOI 10.23812/20-Editorial-Kritas
  30. Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049
  31. Li G, 2020, J MED VIROL, V92, P424, DOI 10.1002/jmv.25685
  32. Mantri CK, 2019, J CLIN INVEST, V129, P1094, DOI 10.1172/JCI122530
  33. Marone G, 2016, INT ARCH ALLERGY IMM, V171, P158, DOI 10.1159/000452889
  34. Marshall JS, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174241
  35. Mauad T, 2010, AM J RESP CRIT CARE, V181, P72, DOI 10.1164/rccm.200909-1420OC
  36. Pagano JS, 2004, SEMIN CANCER BIOL, V14, P453, DOI 10.1016/j.semcancer.2004.06.009
  37. Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141
  38. Recalcati S, 2020, J EUR ACAD DERMATOL, V34, pE212, DOI 10.1111/jdv.16387
  39. Sarzi-Puttini P, 2020, CLIN EXP RHEUMATOL, V38, P337
  40. Schroeder JT, 2005, J IMMUNOL, V175, P5724, DOI 10.4049/jimmunol.175.9.5724
  41. Singhal T, 2020, INDIAN J PEDIATR, V87, P281, DOI 10.1007/s12098-020-03263-6
  42. SUEKI H, 1995, J INVEST DERMATOL, V105, P704, DOI 10.1111/1523-1747.ep12324502
  43. Sundstrom JB, 2004, J IMMUNOL, V172, P4391, DOI 10.4049/jimmunol.172.7.4391
  44. Tang X, 2020, CHEST, V158, P195, DOI 10.1016/j.chest.2020.03.032
  45. Teach SJ, 2015, J ALLERGY CLIN IMMUN, V136, P1476, DOI 10.1016/j.jaci.2015.09.008
  46. Troupin A, 2016, J IMMUNOL, V197, P4382, DOI 10.4049/jimmunol.1600846
  47. Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x
  48. Wada Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035069
  49. Waldman M, 2005, LUPUS, V14, P19, DOI 10.1191/0961203305lu2054oa
  50. Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X
  51. Zhang Y, 2020, Zhonghua Xue Ye Xue Za Zhi, V41, P302, DOI [10.3760/cma.j.issn.0253-2727.2020.0006, 10.3760/cma.j.issn.0253-2727.2020.008]

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDT
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/05
Artigos e Materiais de Revistas Científicas - LIM/06
Carregar mais